Ultragenyx Pharmaceutical
RARE
16.48
-0.74
-4.30%
Ultragenyx Pharmaceutical
US · RARE
#3012 by market cap
Listed 1970
16.48
-0.74
-4.30%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:31
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 24 in the most recent period (2026/Q3).
- Total institutional ownership rose 7.0 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 117.65% +7.01pp
- Institutions
- 364 -24
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund67.43%
Hedge Fund36.94%
Public Company5.44%
VC/PE Fund4.01%
Individual/Insider3.49%
Private Company2.40%
Insurance Company0.51%
Government Pension Fund0.36%
Endowment Fund0.25%
Family Office/Trust0.25%
Top holders as of 2026-09-30
BlackRock
11.25% · 11.43M sh
Vanguard Portfolio Management, LLC
8.28% · 8.42M sh
RTW Investments, LP
7.67% · 7.80M sh
State Street Global Advisors
7.42% · 7.54M sh
AQR Capital Management
6.43% · 6.53M sh
Madison Avenue Partners, LP
6.21% · 6.31M sh
Vanguard Capital Management, LLC
4.23% · 4.30M sh
Two Sigma Investments, LP
3.56% · 3.62M sh
Sands Capital Management, LLC
3.11% · 3.16M sh
Frontier Capital Management
2.90% · 2.85M sh
Jacobs Levy Equity Management Inc
2.89% · 2.94M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| Emil Kakkis | Chief Executive Officer | 2.71% |
| Thomas Kassberg | Former Chief Business Officer & Executive VP | 0.23% |
| Dennis Huang | Chief Technical Operations Officer and Executive VP of Gene Therapy Operations | 0.10% |
| John Pinion | Chief Quality Operations Officer & Executive VP of Translational Sciences | 0.08% |
| Erik Harris | Executive Vice President | 0.06% |
| Eric Crombez | Chief Medical Officer & Executive VP | 0.05% |
| Karah Parschauer | Chief Legal Officer & Executive VP of Corporate Affairs | 0.04% |
| Michael Narachi | Independent Director | 0.03% |
| Daniel Welch | Independent Non-Executive Chairperson | 0.03% |
| Theodore Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-14 | Howard Horn | Executive VP of Corporate Strategy & CFO | Open Market Disposition | -7,066 | $15.27 |
| 2026-09-14 | Theodore Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | Open Market Disposition | -1,283 | $13.57 |
| 2026-09-02 | Theodore Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | Open Market Disposition | -161 | $13.99 |
| 2026-08-02 | Howard Horn | Executive VP of Corporate Strategy & CFO | Open Market Disposition | -4,696 | $24.92 |
| 2026-08-02 | Karah Parschauer | Chief Legal Officer & Executive VP of Corporate Affairs | Open Market Disposition | -1,900 | $24.92 |
| 2026-06-30 | Howard Horn | Executive VP of Corporate Strategy & CFO | Open Market Disposition | -4,698 | $33.13 |
| 2026-06-14 | Corazon Sanders | Independent Director | Open Market Disposition | -2,000 | $25.05 |
| 2026-06-14 | Karah Parschauer | Chief Legal Officer & Executive VP of Corporate Affairs | Open Market Disposition | -1,899 | $24.62 |
| 2026-05-31 | Howard Horn | Executive VP of Corporate Strategy & CFO | Open Market Disposition | -4,653 | $23.77 |
| 2026-05-17 | Shehnaaz Suliman | Independent Director | Open Market Disposition | -5,740 | $25.12 |
| 2026-05-13 | Daniel Welch | Independent Non-Executive Chairperson | Other Acquisition | +7,751 | -- |
| 2026-05-13 | Daniel Welch | Independent Non-Executive Chairperson | Other Derivative Acquisition | +14,058 | $25.80 |
| 2026-05-13 | Matthew Fust | Independent Director | Other Acquisition | +7,751 | -- |
| 2026-05-13 | Matthew Fust | Independent Director | Other Derivative Acquisition | +14,058 | $25.80 |
| 2026-05-13 | Shehnaaz Suliman | Independent Director | Other Acquisition | +7,751 | -- |
| 2026-05-13 | Shehnaaz Suliman | Independent Director | Other Derivative Acquisition | +14,058 | $25.80 |
| 2026-05-13 | Deborah Dunsire | Independent Director | Other Acquisition | +7,751 | -- |
| 2026-05-13 | Deborah Dunsire | Independent Director | Other Derivative Acquisition | +14,058 | $25.80 |
| 2026-05-13 | Corazon Sanders | Independent Director | Other Acquisition | +7,751 | -- |
| 2026-05-13 | Corazon Sanders | Independent Director | Other Derivative Acquisition | +14,058 | $25.80 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:31:44 · For reference only, not investment advice and not tailored to your situation.
Ultragenyx Pharmaceutical discussion 0 comments